Private equity in healthcare: Cardiologists, government officials and advocacy groups share their perspective

The increasing presence of private equity (PE) investments in cardiology and other healthcare specialties continues to be one of the year’s biggest stories. What do cardiologists and other stakeholders feel about this ongoing trend? There appears to be a fair amount of concern and trepidation, judging by a series of public comments submitted to the Federal Trade Commission (FTC) and other federal agencies.

Back in March, the FTC, U.S. Department of Justice, and U.S. Department of Health and Human Services launched a public inquiry to learn more about how physicians, patients, insurance providers and other stakeholders felt about PE’s growing influence in the U.S. healthcare system.

“When PE firms buy out healthcare facilities only to slash staffing and cut quality, patients lose out,” FTC Chair Lina M. Khan said at the time, making her opinion about the growing trend quite clear. “Through this inquiry, the FTC will continue scrutinizing private equity roll-ups, strip-and-flip tactics, and other financial plays that can enrich executives but leave the American public worse off.”

The deadline for public comment was Wednesday, June 5. With that date now in the rearview mirror, Cardiovascular Business jumped into the responses to learn more about what people had to say about this ongoing trend.

American College of Cardiology discusses ‘opportunities,’ ‘challenges’ associated with private equity

The American College of Cardiology (ACC) opened its response by highlighting the importance of “promoting competition while safeguarding patient interests.”

“Capital investments in healthcare can bring both opportunities and challenges for practices,” wrote ACC President Cathie Biga, MSN, RN. “They can inject needed funds, drive innovation, and enhance operational efficiencies, ultimately benefiting patients and the healthcare system. However, valid concerns exist regarding potential negative impacts on competition, rapid growth/expansion, access to care, and the autonomy of healthcare clinicians. Clinicians must have the freedom to exercise their professional judgment without undue influence from external parties, including financial incentives, administrative mandates or corporate interests.”

Biga encouraged federal agencies to perform a “comprehensive examination of healthcare market dynamics” that included a close look at how PE investments may affect competition in healthcare, patient safety, transparency and accountability. In addition, the ACC believes these agencies should look for new ways to strengthen regulatory oversight in a way that can ensure “transactions align with the interests of patients and the public.”

Government officials, including 11 attorneys general, weigh in

Sen. Elizabeth Warren, already known as an outspoken opponent of PE investments in healthcare, used the public inquiry as an opportunity to summarize her thoughts on the topic.

“As you move forward with your inquiry, I urge you to continue to closely scrutinize, promulgate regulations regarding and take appropriate enforcement actions against vertically integrated insurers, PE firms, and pharmaceutical companies that are driving healthcare consolidation—a trend that has enriched corporate actors at the expense of patients’ health and financial security, taxpayer dollars and healthcare providers’ clinical autonomy,” she said.

Elizabeth Warren

Sen. Elizabeth Warren, D-Mass. 

Warren detailed the “corporate greed” she sees throughout our modern healthcare system, noting that the Medicare Advantage program may be the single worst offender of them all. She called out the practices of upcoding, for example, while exploring how care denials regularly allow “vertically integrated insurers to disadvantage competitors.”

Another key takeaway from Warren’s response was the fact that PE companies “often engage in a series of small acquisitions to fly under the radar of antitrust scrutiny.”

“Serial roll-ups have become pervasive in the healthcare industry and have resulted in market dominance leading to higher prices, particularly when PE  has been involved,” she wrote. “It is important that your agencies consider this trend in healthcare acquisitions and take a holistic view of market dominance in order to prevent harms to competition and patients.”

Another response that stood out was the 30-page evaluation filed by 11 U.S. attorneys general. California Attorney General Rob Bonta, Connecticut AG William Tong, Delaware AG Kathleen Jennings, Illinois AG Kwame Raoul, Minnesota AG Keith Ellison, New Jersey AG Matthew J. Platkin, Oregon AG Ellen Rosenblum, Pennsylvania AG Michelle A. Henry, Rhode Island AG Peter Neronha, Washington AG Bob Ferguson and Washington, D.C., AG Brian Schwalb all signed the response.

The officials shared their many concerns about consolidation in healthcare, noting that it could have a negative impact on patients. They also noted that PE firms often take full control of the companies they acquire, with “very little of their own funds at stake.” This can cause the firms to take larger risks than they would otherwise, the attorneys general wrote, “pushing the envelope” in a way that can be quite damaging.

The group also highlighted the “lack of transparency” that is often associated with PE investments.

“This is an intentional feature of the PE business model, and it can exacerbate many of the other incentives discussed by masking conduct from investors who may be more risk-averse than the PE firms, due to their larger investment in the funds,” the AGs wrote.

Another key concern of the group is the fact that physicians who have their practices sold to PE firms may be surprised to learn that the benefits are not as significant as they were led to believe.

“PE promises physician practices capital and technology that would otherwise be difficult for independent physician practices to acquire,” the attorneys general wrote. “However, the funding comes with significant concerns. PE firms tend to focus on short-term profits, which increases prices for consumers by having physicians increase the use of expensive treatments and services rather than seeking out lower cost options. Acquisition by PE increases the debt burden of physician practices, which heightens their risk of failure.”

Advocacy groups highlight physician concerns

The Physicians Advocacy Institute (PAI), a nonprofit group focused on advancing “fair and transparent payment policies,” issued its own 28-page evaluation of the negative impact consolidation and PE could have on patient care in the United States.

“Runaway healthcare consolidation poses enormous risks for patients and the physicians who serve them,” PAI CEO Kelly Kenney said in a statement highlighting the group’s response. “As corporate entities buy up more and more physician practices, physicians are rightly concerned that corporations’ allegiance is with shareholders first, putting patients at risk.”

The group fears that patient care, access and healthcare costs will all suffer if these trends continue, noting that the “nature of PE transactions can contribute to a deterioration in a practice’s financial stability.”  

PAI included multiple recommendations in its assessment. The institute suggested that physicians involved in these transactions should “retain clinical autonomy,” for example, and wrote that an increase in regulatory oversight is necessary to ensure PE firms don’t push too hard and do permanent damage to the practices they acquire. The group also recommended modifying payment policies so that consolidation does not make as much financial sense in the future. Passing the right legislation could even cause physicians to wish to return to private practice, PAI contended.

Another advocacy group, the Coalition for Patient-Centered Care (CPCC), presented its own thoughts on the topic. Drawing from the perspective of more than 13,000 physicians, CPCC shared its fear that the rise of PE could impact patient care in a negative way.

“We believe that everyone benefits when physicians have the freedom to exercise their best judgment as to the delivery of care and can work directly with their patients to make medical decisions and deliver patient-centered care,” the group wrote. “PE firms do not share this ideal.”

Cardiologist details positive experience with private equity

An electrophysiologist in New jersey shared his positive experience with PE, noting that after his group was acquired, it “has not changed or influenced one thing about the way we practice medicine.”

Edmund Karam, MD, wrote that he and his colleagues have seen considerable savings since the transaction was finalized, with the organization moving more exams to the outpatient setting. They are also able to negotiate better prices now, he said, “which helps our financial stability.”

“I am sure that you will hear negatives stories about PE involvement in healthcare, but it really all depends on the individual situation,” he wrote. “A failing practice is not going to be magically restored by private equity acquisition. There has to be good substrate to begin with: Physicians and team members who are committed to working hard, yet efficiently, for their patients.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.